Abstract
Ruthenium compounds offer improved selectivity and fewer side effects compared to platinum-based drugs in glioblastoma treatment. Insights into their interactions with transferrin suggest targeted drug delivery, while photoactivated chemotherapy is a novel cytotoxic approach in tumor tissues.
MeSH terms
-
Animals
-
Antineoplastic Agents* / chemistry
-
Antineoplastic Agents* / pharmacology
-
Antineoplastic Agents* / therapeutic use
-
Brain Neoplasms* / drug therapy
-
Brain Neoplasms* / metabolism
-
Brain Neoplasms* / pathology
-
Drug Delivery Systems
-
Glioblastoma* / drug therapy
-
Glioblastoma* / metabolism
-
Glioblastoma* / pathology
-
Humans
-
Ruthenium Compounds* / chemistry
-
Ruthenium Compounds* / pharmacology
-
Ruthenium Compounds* / therapeutic use
-
Transferrin / chemistry
-
Transferrin / metabolism
Substances
-
Antineoplastic Agents
-
Ruthenium Compounds
-
Transferrin